{"url":"https://newsforagent.com/news/2026-10-18/antheia-war-department-conditional-loan","markdown_url":"https://newsforagent.com/news/2026-10-18/antheia-war-department-conditional-loan.md","title":"Antheia Lands $80 Million War Department Loan","headline":"Antheia Secures $80 Million Conditional Loan From War Department's OSC","description":"Antheia received an $80 million conditional loan from the Department of War's Office of Strategic Capital to onshore production of key drug ingredients.","section":"Funding","published_at":"2026-10-18T02:17:51+00:00","modified_at":"2026-10-18T02:17:51+00:00","author":"News Desk","key_takeaways":["The Department of War's Office of Strategic Capital committed an $80 million conditional loan to Antheia.","Antheia uses bioengineered yeast to convert sugar into key starting materials and active pharmaceutical ingredients in a one-step fermentation process.","The conditional loan requires Antheia to satisfy financial, legal, technical, investment and due diligence requirements before financial close."],"companies":[{"name":"Antheia","is_primary":true,"profile_url":"https://akta.pro/company-profiles/000052q/antheia","website":"http://www.antheia.bio"}],"source":{"publisher":"Mirage News","title":"War Department Commits $80 Million Loan to Antheia","url":"https://www.miragenews.com/war-department-commits-80-million-loan-to-1762199/"},"other_sources":[],"tags":["Funding","Antheia"],"body_markdown":"The Department of War's Office of Strategic Capital announced an $80 million conditional loan commitment with Antheia, Inc. to scale domestic production of key starting materials and active pharmaceutical ingredients for generic drugs. [Mirage News](https://www.miragenews.com/war-department-commits-80-million-loan-to-1762199/) reported the commitment on October 18, 2026.\n\n## Antheia's $80 Million Conditional Loan\n\nThe OSC investment, alongside additional private capital, is intended to support [Antheia](https://akta.pro/company-profiles/000052q/antheia)'s domestic biomanufacturing efforts to secure critical medicine supply chains. The company specializes in using bioengineered yeast to convert sugar directly into KSMs and APIs in a one-step fermentation process. Antheia currently produces its pipeline of KSMs and APIs with contract manufacturing partners abroad due to a lack of available and adequate domestic manufacturing capacity.\n\n\"Antheia's biosynthesis platform represents an innovative method to establish cost-effective domestic supply chains which enable to the United States to compete globally,\" said David A. Lorch, Director of the Office of Strategic Capital and Senior Advisor to Deputy Secretary of War Steve Feinberg.\n\n\"OSC's investment in Antheia represents an exciting opportunity to establish domestic supply chains for the production of KSMs and APIs that are critical to our most important pharmaceuticals,\" said Akshaya Trivedi, Managing Director (Investments) with OSC.\n\n\"I applaud the Office of Strategic Capital on this important conditional investment which advances the onshoring of pharmaceutical supply chains,\" said Emil Michael, Under Secretary of War for Research and Engineering.\n\nThe conditional loan commitment specifies additional steps Antheia must complete before financial close, including satisfying various financial, legal, technical, investment, due diligence, and other requirements. OSC's conditional financing would enable Antheia to establish its U.S. manufacturing operations, onshore essential medicine supply chains, and ultimately reduce the risk of essential medicine shortages.\n\n## Antheia's Funding and Government Agreements\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Antheia closed a second tranche of Series C financing for $24 million in January 2026 led by ATHOS KG and America's Frontier Fund, bringing total capital raised over the past year to more than $175 million. The same records show the company's total funding at $244.1 million.\n\n| Funding round | Amount | Lead investors |\n| --- | --- | --- |\n| Series C (2025-06) | $56 million | EDBI, Global Health Investment Corporation |\n| Grant (2024-12) | $12 million | U.S. Department of Health & Human Services |\n| Grant (2024-07) | $11 million | BioMaP-Consortium |\n\n## Antheia's Earlier Government Agreements\n\nIn March 2026, Antheia secured an additional $9 million from the BioMaP-Consortium under the DPA Title III Program, expanding total project investment to $21 million for domestic commercial-scale production of two critical pharmaceutical ingredients, according to akta.pro company records. The same records show that ASPR announced an investment in Antheia in March 2026 for domestic production of thebaine, used in pain management, alcohol use disorder treatments, and opioid overdose reversal drugs.\n\nIn November 2025, TAPI and Antheia announced a strategic partnership to scale production of biosynthetic APIs and KSMs using TAPI's fermentation expertise and manufacturing footprint in Europe, the same records show.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}